Related Experiment Video
Updated: Jan 3, 2026
10:56
A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
Published on: September 15, 2018
8.4K
HMG-CoA Reductase as Target for Drug Development
Baskaran Gunasekaran1, Mohd Yunus Shukor2
1Faculty of Biotechnology and Biomolecular Sciences, Department of Biochemistry, Universiti Putra Malaysia, Serdang, Selangor, Malaysia.
Methods in Molecular Biology (Clifton, N.J.)
|November 28, 2019
Summary
Researchers are developing new cholesterol-lowering drugs by inhibiting HMG-CoA reductase. Enzyme activity assays and the four-parameter logistics model are crucial for assessing drug potency and IC50 values.
Area of Science:
- Biochemistry
- Pharmacology
- Drug Discovery
Background:
- High cholesterol management primarily involves inhibiting NADPH-dependent HMG-CoA reductase (3-hydroxy-3-methyl-glutaryl-CoA reductase).
- Statins, widely used since the 1970s, target this enzyme but newer, safer alternatives are under development.
- HMG-CoA reductase inhibition remains a central focus in therapeutic agent research.
Purpose of the Study:
- To outline methods for assessing HMG-CoA reductase enzyme activity.
- To evaluate the potency of potential therapeutic agents, including plant and microbial extracts.
- To detail the application of the four-parameter logistics model for IC50 value determination.
Main Methods:
- Enzyme activity assays for HMG-CoA reductase.
- Inhibition studies using candidate drugs and natural extracts.
- Statistical analysis using the four-parameter logistics model to determine IC50 values and confidence intervals.
Main Results:
- Accurate assessment of enzyme inhibition is vital for drug development.
- The four-parameter logistics model provides reliable IC50 estimations.
- This methodology supports the evaluation of novel cholesterol-lowering agents.
Conclusions:
- Assessing HMG-CoA reductase inhibition is key to developing effective cholesterol-lowering therapies.
- The described methods facilitate the discovery and validation of new drug candidates.
- Accurate IC50 determination using the four-parameter logistics model is essential for drug potency assessment.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
01:26Targets for Drug Action: Overview
9.9K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
9.9K
01:31Transducer Mechanism: Nuclear Receptors
2.3K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
2.3K
01:27Phase I Reactions: Reductive Reactions
509
Phase I biotransformation reductive reactions are chemical processes that modify drugs by introducing or revealing polar functional groups via reduction. Enzymes called reductases catalyze these reactions, playing a pivotal role in drug metabolism by transforming lipophilic drugs into more polar, water-soluble metabolites for easy excretion. An essential type of reductive reaction is the carbonyl group reduction, where aldehydes and ketones are reduced to alcohols. An example is the...
509
01:26Atherosclerosis III: Management
285
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
285
02:17Reduction of Alkenes: Asymmetric Catalytic Hydrogenation
3.8K
Catalytic hydrogenation of alkenes is a transition-metal catalyzed reduction of the double bond using molecular hydrogen to give alkanes. The mode of hydrogen addition follows syn stereochemistry.
The metal catalyst used can be either heterogeneous or homogeneous. When hydrogenation of an alkene generates a chiral center, a pair of enantiomeric products is expected to form. However, an enantiomeric excess of one of the products can be facilitated using an enantioselective reaction or an...
The metal catalyst used can be either heterogeneous or homogeneous. When hydrogenation of an alkene generates a chiral center, a pair of enantiomeric products is expected to form. However, an enantiomeric excess of one of the products can be facilitated using an enantioselective reaction or an...
3.8K